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Abstract
Circular RNAs (circRNAs) play important roles in cancer tumorigenesis and progression, representing prognostic
biomarkers and therapeutic targets. In this case, we demonstrated the role of circ-NOLC1 in epithelial ovarian cancer
(EOC). Our results have shown that Circ-NOLC1 expression was higher in EOC tissues than in normal tissues, and was
positively associated with FIGO stage, differentiation. Among ovarian cancer cell lines, circ-NOLC1 expression was the
highest in A2780, and lowest in CAOV3. Overexpression of circ-NOLC1 in CAOV3 cells increased cell proliferation,
migration, and invasion ability, whereas silencing of circ-NOLC1 in A2780 cells had the opposite effect: however,
neither circ-NOLC1 downregulation nor overexpression influenced NOLC1 mRNA expression. In nude mice with
subcutaneous tumors, circ-NOLC1 downregulation decreased tumor growth. Bioinformatic analysis and RNA-binding
protein immunoprecipitation showed that circ-NOLC1 could bind to ESRP1. In addition, the overexpression of circ-
NOLC1 significantly increased ESRP1, RhoA, and CDK1 protein and mRNA expression level; circ-NOLC1 downregulation
had the opposite effects. The tumor-promoting effect of circ-NOLC1 was inhibited by knockdown of ESRP1, CDK1, or
RhoA expression in circ-NOLC1-overexpressing cells, which might act by modulating RhoA and CDK1 expression. In
conclusion, our study demonstrated that Circ-NOLC1 might promote EOC tumorigenesis and development by binding
ESRP1 and modulating CDK1 and RhoA expression.
Introduction
Ovarian cancer is a malignant tumor that seriously
threatens women’s health1–3. Asymptomatic clinical
appearance in the disease’s progression, resulting in
widespread disease in the pelvic and abdominal cavity.
Therefore, even though surgery, chemotherapy, and bio-
logical therapy are used widely to treat ovarian cancer, the
5-year survival rate remains at only 35–38%4,5. Thus,
research into the mechanism of ovarian cancer develop-
ment is important for its early detection, diagnosis, and
treatment.
The occurrence and development of ovarian cancer is a
complex process, comprising multi-step, multi-gene, and
multi-factor regulations, especially the regulation of
transcription factor regulatory networks, signaling path-
ways, and regulatory loops. Recent studies have shown
that non-coding RNAs also play an important role in the
process of ovarian cancer proliferation, apoptosis, inva-
sion, and metastasis6.
Non-coding RNAs are RNA molecules in the tran-
scriptome that are not translated into proteins, including
small nuclear RNAs, small nucleolar RNAs, microRNAs
with relatively small molecular weight (miRNAs), piwi-
interacting RNAs, long non-coding RNAs, and circular
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RNAs (circRNAs) with relatively large molecular weights.
CircRNAs are endogenous RNAs that are widely dis-
tributed in eukaryotic cells and have a stable cyclic
structure, playing a vital role in the regulation of gene
expression. Their unique covalently closed loop structure
means that they lack a 5′-end cap structure and 3′ term-
inal polyadenylation (polyA) tail, which is characterized
by tolerance to exonucleases and makes them more stable
than homologous linear RNA7–9. CircRNAs play vital
roles in almost all kinds of cancer and have the potential
to be used as novel biomarkers and therapeutic targets for
cancer diagnosis and treatment through their functions as
microRNA (miRNA) molecular “sponges”10–12, protein
translators13, and gene transcription regulators14. For
example, circTCF25 overexpression promoted cell pro-
liferation and migration by downregulating miR-103a-
3p/-107 expression and increasing CDK6 (cell-dependent
kinase 6) expression in vitro or in vivo11. Recent studies
also revealed that circRNAs could function as RNA-
binding protein sponges15. For example, circ-Foxo3 can
inhibit CDK2 (cell-dependent kinase 2) and induce cell
cycle arrest through a circ-Foxo3-p21-CDK2 ternary
complex16. However, there are relatively few studies on
circRNAs in ovarian cancer.
We detected 12,723 expressed circRNAs in ovarian
cancer and normal ovarian tissue through circRNA gene
chip, and further screened circRNAs with differential
expression up to fivefold, which identified circ-NOLC1.
Nucleolar and coiled-body phosphoprotein 1 (NOLC1,
also known as Nopp140) is a protein with transcription-
like activity, which involves in nuclear assembly17 and
precursor rRNA cleavage18, as a novel nucleolar GTPase/
ATPase, it was reported to have a role in the process of
the tumorigenesis and progression such as cell cycle, cell
proliferation19, cell migration, and invasion. Similar to
linear RNA, circRNA is also derived from the transcrip-
tion of parental genes, and its uniqueness lies in the
alternative splicing of the non-classical form of RNA
precursors. The most common one is exon reverse spli-
cing, that is, circRNA molecules is generated by back-
splicing, where downstream exons are spliced to upstream
exons in reverse order, leading to a circular transcript20.
According to gene chip, the precursor RNA of NOLC1
can also form exonic circRNA circ-NOLC1 at exon 1–4
through back-splicing. However, the circular structure of
circ-NOLC1, its relationship with NOLC1, and the most
important, its role in ovarian cancer tumorigenesis and
progression remains unclear.
Therefore, in the present study, we investigated the role
of circ-NOLC1 in ovarian cancer and attempted to
determine how circ-NOLC1 affects the development of
ovarian cancer through a series of in vivo and in vitro
experiments.
Results
The relationship between the circ-NOLC1 expression level
and the clinicopathological characteristics of ovarian
cancer
Circ-NOLC1 expression in normal ovarian tissues,
benign tissues, borderline tumor tissues, and ovarian
carcinoma tissues was assessed using quantitative real-
time reverse transcription PCR (qRT-PCR). The results
showed that circ-NOLC1 expression was significantly
higher in borderline and ovarian cancers than in normal
and benign ovarian tissues (Fig. 1A, p < 0.05, Table 1).
Circ-NOLC1 expression in stage II–IV disease was higher
than in stage I (Fig. 1B, p < 0.05). In addition, the
expression of circ-NOLC1 in the moderately and poor
pathological differentiation was higher than that in the
well differentiation (Fig. 1C, *p < 0.05). Besides, the
expression of circ-NOLC1 was also higher in CA125
positive (>35 U/ml) ovarian cancer patients (Fig. 1D, *p <
0.05, Table 2). These results suggested that circ-NOLC1
involves in the tumorigenesis and progression of ovarian
cancer, and may have potential to be treated as diagnostic
biomarker.
circ-NOLC1 functions independently from the NOLC1 gene
We determined circ-NOLC1 expression in six ovarian
cancer cell lines using qRT-PCR. Circ-NOLC1 showed the
highest expression level in A2780 cells and the lowest in
CAOV3 cells (Fig. 2A); therefore, A2780 cells were used
for circ-NOLC1 short hairpin RNA (shRNA) transfection,
whereas CAOV3 cells were used for circ-NOLC1 over-
expression plasmid transfection. QRT-PCR was used to
confirm the transfection efficiency (Fig. 2B, C, *p < 0.05).
Besides, we found that the NOLC1 mRNA expression
level did not change after circ-NOLC1 overexpression
(Fig. 2D, p > 0.05) or downregulation (Fig. 2E, p > 0.05),
thus we speculated that circ-NOLC1 functions indepen-
dently of the NOLC1 gene.
The effect of circ-NOLC1 in vitro and in vivo
Ovarian cancer cell proliferation, migration, and inva-
sion were assessed through CCK8, plate clone, cell
apoptosis, wound healing, and transwell assays. The
results indicated that circ-NOLC1 overexpression in
CAOV3 cells significantly induced cell proliferation
(Fig. 3A, p < 0.05) and clonal formation (Fig. 3B, p < 0.05);
reduced cell apoptosis (Fig. 3C, p < 0.05); and induced cell
migration (Fig. 3D, p < 0.05) and invasion (Fig. 3E, p <
0.05), which means that circ-NOLC1 functions as an
“oncogene” in ovarian cancer. Compared with the nega-
tive control, after circ-NOLC1 downregulation using circ-
NOLC1 shRNA transfection in A2780 cells, cell pro-
liferation (Fig. 4A, p < 0.05) and clonal formation (Fig. 4B,
p < 0.05) were significantly inhibited, whereas cell
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apoptosis was induced (Fig. 4C, p < 0.05), and cell
migration (Fig. 4D, E, p < 0.05, Supplementary videos 1 &
2) and invasion (Fig. 4F, p < 0.05) were decreased. Nude
mice xenograft assays demonstrated that the tumor-
igenicity was inhibited in mice injected with circ-NOLC1-
downregulated A2780 cells (Fig. 5D; p < 0.05) compared
with that in the control group (Fig. 5A, B), and the tumor
volumes were smaller in the circ-NOLC1 downregulation
group (Fig. 5C; p < 0.05).
The correlation between circ-NOLC1 and ESRP1
Bioinformatic prediction showed that circ-NOLC1 has
binding sites for miR-326-5p, miR-330, miR-370, and
miR-9-5p (Circular RNA Interactome, https://
circinteractome.irp.nia.nih.gov/), and these miRNAs also
have binding sites for RhoA and CDK1 mRNA (mirDIP,
http://ophid.utoronto.ca/mirDIP/index.jsp). Using wes-
tern blotting, we confirmed that circ-NOLC1 over-
expression induced RhoA and CDK1 protein expression,
while circ-NOLC1 downregulation inhibited RhoA and
CDK1 protein expression both in vivo and in vitro
(Figs. 5E and 6A). However, the results of dual-luciferase
reporter assay indicated that circ-NOLC1 might not bind
with miR-326-5p, miR-330, miR-370, and miR-9-5p
(Supplementary Fig. 1). Bioinformatic prediction soft-
ware (catRAPID, http://s.tartaglialab.com/page/
catrapid_group) revealed that ESRP1 could bind with
circ-NOLC1 (Supplementary Fig. 2), which we confirmed
experimentally using a RIP assay. RNA obtained from the
RIP assay using an anti-ESRP1 antibody was subjected to
qPCR analysis, which demonstrated the enrichment of
circ-NOLC1 (Fig. 6B). We also confirmed that circ-
NOLC1 overexpression could induce ESRP1 protein
expression, whereas circ-NOLC1 downregulation inhib-
ited ESRP1 protein expression. Besides, through qRT-
PCR, we confirmed that circ-NOLC1 overexpression
induced ESRP1, RhoA, and CDK1 mRNA expression,
whereas circ-NOLC1 downregulation inhibited ESRP1,
RhoA, and CDK1 mRNA expression (Fig. 6C, D).
Silencing ESRP1, CDK1 or RhoA could reverse circ-NOLC1’s
function as an oncogene
Silencing ESRP1 in circ-NOLC1-overexpressing CAOV3
cells significantly reduced cell viability (Fig. 7A, p < 0.05)
and clonal formation (Fig. 7B, p < 0.05), induced apoptosis
(Fig. 7C, p < 0.05), and reduced cell migration (Fig. 7D, p
< 0.05) and invasion (Fig. 7E, p < 0.05). Furthermore,
knockdown of ESRP1 reversed the ability of circ-NOLC1
to upregulate RhoA and CDK1 protein expression in circ-
NOLC1-overexpressing CAOV3 cells (Fig. 7F). These
results showed that ESRP1 has a key role during the
tumor-promoting process of circ-NOLC1. What’s more,
we also found significantly reduced cell viability (Fig. 8A,
p < 0.05), cell migration (Fig. 8B, p < 0.05) and invasion
(Fig. 8C, p < 0.05) ability neither after CDK1 or RhoA
downregulation in circ-NOLC1-overexpressing CAOV3
cells, however, ESRP1 protein expression level did not
change after neither after CDK1 or RhoA knockdown
(Fig. 8D). Thus, we hypothesized that circ-NOLC1 might
participate in ovarian cancer tumorigenesis and progres-
sion by binding the ESRP1, thus modulating RhoA and
CDK1 expression.
Discussion
The results of the present study have showed that circ-
NOLC1 expression was significantly higher in ovarian
cancer tissues than in normal ovarian tissues. Circ-
NOLC1 expression in FIGO stage II–IV disease was
higher than that in stage I, and in moderate and poor
differentiation than in the well differentiation ovarian
cancer tissues. Besides, the expression of circ-NOLC1 was
also higher in CA125 positive ovarian cancer patients.
Thus, we hypothesized that circ-NOLC1 might partici-
pate in ovarian cancer tumorigenesis and progression.
Furthermore, in vitro, circ-NOLC1 overexpression
induced cell growth, migration, and invasion, whereas
silencing of circ-NOLC1 decreased cell growth, migration,
(see figure on previous page)
Fig. 1 The relationship between circ-NOLC1 expression and the clinicopathological characteristics of ovarian cancer. A Circ-NOLC1
expression in normal ovaries (n= 15), benign ovarian tumors (n= 11), borderline tumors (n= 11) and ovarian carcinomas (n= 118) was analyzed by
qRT-PCR. B FIGO stages: The expression of circ-NOLC1 in stage II–IV (n= 96) was higher than that in stage I (n= 22). C Pathology classification: circ-
NOLC1 expression in the moderate (Mod) and Poor differentiation (n= 100) was higher than in the well differentiation (n= 18). D CA125: circ-NOLC1
expression in the CA125 positive (n= 109) was higher than in the CA125 negative (n= 9) patients. Data are expressed as the mean ± SD. Correlation
between circ-NOLC1 expression and clinicopathological characteristics were examined using the χ2 test. *p < 0.05.
Table 1 circ-NOLC1 expression in different ovarian
tissues.
Groups N TDRG1 expression/18 s P value
Normal ovary 15 3.57013E-06 ± 3.29678E-06 0.0015
Benign ovarian tumor 11 5.86156E-06 ± 9.77477E-06 0.0108
Borderline ovarian tumor 11 1.23827E-05 ± 2.21106E-05
Ovarian carcinoma 118 2.03776E-05 ± 5.94288E-05
Omentum tumor 20 1.68522E-05 ± 3.81715E-05
Bold and italics means P < 0.05.
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and invasion. In addition, nude mice xenograft assays also
demonstrated reduced tumorigenicity in mice injected
with circ-NOLC1-downregulated A2780 cells. However,
neither circ-NOLC1 downregulation nor overexpression
influence NOLC1 mRNA expression. Thus, we hypothe-
sized that circ-NOLC1 functions independently of
NOLC1, which prompted the question: how does circ-
NOLC1 function as an oncogene?
CircRNAs have attracted much attention recently, and
studies have shown that circRNAs participate in cancer
development in many ways. The most common function
of circRNAs is as miRNA sponges, thereby releasing the
inhibition of the miRNAs’ target mRNAs. Through
bioinformatic analysis, we found that circ-NOLC1 has
binding sites for a series of miRNAs such as miR-326-5p,
miR-330, miR-370, and miR-9-5p, and that these miRNA
also have binding sites with RhoA and CDK1.
Ras homologous family member A (RhoA) is a small
molecule G protein/GTPase (~22 kDa)21 that regulates
the cytoskeleton and affects cell migration by activating
ROCK and other effector proteins22. Studies have shown
that this mode of regulation is involved in the invasion
and metastasis of various tumors, such as gastric cancer23
and breast cancer24. Our previous research found that
RhoA is overexpressed in ovarian epithelial cancer, and its
expression is positively associated with FIGO stage and
differentiation. RhoA not only affects ovarian cancer
invasion and metastasis, but also affects the occurrence of
ovarian cancer by regulating apoptosis-related genes25.
Cyclin-dependent kinase 1 (CDK1 or CDC2), a member
of the serine/threonine protein kinase family, is the
checkpoint protein for the cell cycle from G2 to M phase
and is involved in a variety of tumorigenic develop-
ments26. Our previous research also proved that CDK1
participates in ovarian cancer tumorigenesis and pro-
gression27. We first assessed RhoA and CDK1 expression
levels after circ-NOLC1 overexpression and down-
regulation. After circ-NOLC1 overexpression or down-
regulation, RhoA and CDK1 protein levels were
significantly upregulated or inhibited, respectively. Thus,
we hypothesized that circ-NOLC1 could promote ovarian
cancer development by binding with miRNAs that inhibit
the translation of CDK1 and RhoA. However, dual-
luciferase reporter assays demonstrated that circ-NOLC1
might not directly bind with miR-326-5p, miR-330, miR-
370, or miR-9-5p, leaving open the question of how circ-
NOLC1 influences RhoA and CDK1 expression.
Studies have shown that despite functioning as miRNA
sponges, circRNAs might also function in other ways,
such as regulating transcription and acting as enzyme
scaffolds. Recently, researchers showed that circRNAs
could function by enabling circRNA-protein interac-
tions28. For example, Abdelmohsen et al.29 reported that
the extensive binding of Hu-Antigen R (HuR) to circ-
PABPN1 prevents its binding to poly(A) binding protein
nuclear 1 (PABPN1) mRNA and reduces PABPN1 trans-
lation. In addition, our previous research reported that
circRhoC functions not only as a miR-302e sponge to
positively regulate VEGFA protein expression, but may
also directly bind and modulate VEGFA expression to
Table 2 Correlation of circ-NOLC1 expression with different clinicopathological features of ovarian carcinoma.
Clinicopathological features N circ-NOLC1 expression/18 s P value
The pathology types 0.2795
Serous carcinoma 86 2.20741E-05 ± 6.38584E-05
The other pathology types 32 1.58183E-05 ± 4.60309E-05
Age 0.2531
≤52 62 2.38226E-05 ± 6.41964E-05
>52 56 1.65634E-05 ± 5.39825E-05
CA125 0.0029
≤35 U/ml 9 3.97132E-06 ± 6.6421E-06
>35 U/ml 109 2.17322E-05 ± 6.16323E-05
FIGO stages 0.0144
I 22 6.29372E-06 ± 1.94561E-05
II–IV 96 2.36051E-05 ± 6.48809E-05
Pathology classification 0.0018
Well 18 3.39141E-06 ± 9.26029E-06
Mod+ poor 100 2.34351E-05 ± 6.40101E-05
Bold and italics means P < 0.05.
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promote ovarian cancer development30. Recently, Sun
et al.31 reported that circMYBL2 regulates the translation
efficiency of oncogene FLT3 mRNA by recruiting RNA-
binding protein PTBP1, thereby promoting the occur-
rence and development of FLT3-ITD mutant leukemia,
which demonstrated for the first time that circRNA could
play a positive regulatory role in the translation process in
the form of an RNA-protein complex. Using bioinfor-
matic analysis, we found that circ-NOLC1 could also bind
with proteins such as ESRP1. An extensive literature
search revealed that ESRP1 was also overexpressed in
ovarian cancer tissues; therefore, we suggested that circ-
NOLC1 could bind with ESRP1 and modulating CDK1
and RhoA expression. Through RIP assay we confirmed
that circ-NOLC1 binds with ESRP1. In support of this, we
found that circ-NOLC1 overexpression increased the
ESRP1 protein level, whereas circ-NOLC1 downregulation
has the opposite effect. In addition, the tumor-promoting
effect of circ-NOLC1 was reduced after ESRP1, CDK1, or
RhoA knockdown in circ-NOLC1-overexpressing cells,
thus we hypothesized that circ-NOLC1 might function as
an oncogene through binding and modulating ESRP1,
CDK1, and RhoA levels.
ESRP1 is an epithelial cell-specific RNA-binding pro-
tein that regulates alternative splicing of multiple genes.
Studies indicate that ESRP1 has a critical role in tumor
motility and invasiveness by facilitating cancer cell
escape from primary tumors32. Studies also showed that
ESRP1 promotes breast cancer metastasis by regulating
CD44 mRNA alternative splicing. Besides, high ESRP1
expression indicates a shorter overall survival33.
Fagoonee et al.34 reported that the overexpression of
ESRP1 promotes colorectal cancer development by sti-
mulating cell proliferation. Jeong et al.35 reported that
ESRP1 is overexpressed in ovarian cancer and partici-
pates in the epithelial-mesenchymal transition process.
In addition, after inhibiting ESRP1 expression in circ-
NOLC1 overexpressing CAOV3 cells, RhoA and CDK1
protein levels were decreased, while CDK1 or RhoA
downregulation has no effect on ESRP1 protein level,
which confirmed our suggestion that circ-NOLC1
functions as an oncogene by binding ESRP1 and mod-
ulating CDK1 and RhoA levels. Circ-NOLC1 may bind
to ESRP1 protein, and inhibit protein degradation by
affecting its protein stabilization in the form of an RNA-
protein complex, thereby promoting the expression of
downstream CDK1 and RhoA.
Conclusions
We demonstrated that circ-NOLC1 promotes ovarian
cancer tumorigenesis and development by binding to
ESRP1 and modulating CDK1 and RhoA levels. This is the
Fig. 2 Circ-NOLC1 functions independently from the NOLC1 gene. A Circ-NOLC1 expression in ovarian cancer cell lines was analyzed by qRT-PCR.
Transcription efficiency was analyzed through qRT-PCR after circ-NOLC1 overexpression plasmid transfection B or Circ-NOLC1 shRNA transfection
(C. The NOLC1 mRNA expression level did not change neither after circ-NOLC1 overexpression D nor downregulation (E). Results are representative of
three separate experiments; data are expressed as the mean ± SD. Comparisons between two groups were analyzed using a two-sided Student’s
t test. *p < 0.05.
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first study to suggest that circ-NOLC1 functions in ovarian
cancer and to propose its potential molecular mechanism.
Thus, our findings provide a new perspective for the early
diagnosis and targeted therapy of ovarian cancer.
Materials and methods
Ovarian cancer specimens
Normal ovaries, benign ovarian tumors, borderline
tumors, and ovarian cancer tissues were collected from
Fig. 3 The effects of circ-NOLC1 overexpression in ovarian cancer cells. Circ-NOLC1 overexpression induced cell proliferation A and clonal
formation B; reduced cell apoptosis C; and induced cell migration D and invasion ability (E). The results are representative of three separate
experiments; data are expressed as the mean ± SD. Comparisons between two groups were analyzed using a two-sided Student’s t test. *p < 0.05.
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Fig. 4 The effects of circ-NOLC1 downregulation in ovarian cancer cells. Circ-NOLC1 downregulation reduced cell proliferation A and clonal
formation B; induced cell apoptosis C; and reduced cell migration D & (E, Supplementary video 1: A2780 sh-NC, Supplementary video 2: A2780 sh-
circ-NOLC1) and invasion (F). The results are representative of three separate experiments; data are expressed as the mean ± SD. Comparisons
between two groups were analyzed using a two-sided Student’s t test. *p < 0.05.
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patients who accept gynecological surgery at the First
Affiliated Hospital of China Medical University (She-
nyang, China). After collection, samples were frozen in
liquid nitrogen immediately. The tissue specimen was
confirmed by two pathologists independently. The study
was approved by the Ethics Committee of the China
Medical University (no: 2018-132).
Cell culture and transfection
Human ovarian cancer cell lines A2780, CAOV3, ES-2,
HO8910, OVCAR3, and SKOV3 were purchased from
Jennio Biotech (Guangzhou, China) or ATCC (Manassas,
VA, USA). A2780 and ES-2 cells were cultured in Dul-
becco’s modified Eagle’s medium (HyClone, Logan, UT,
USA); SKOV3 cells were cultured in McCoys’ 5 A;
whereas CAOV3, OVCAR3, and HO8910 cells were cul-
tured in Roswell Park Memorial Institute-1640
(HyClone). All media were supplemented with 10% fetal
bovine serum (FBS) and penicillin/streptomycin (100 U/
mL). The cells were incubated with 5% CO2 at 37 °C.
Lipofectamine 3000 was used for plasmid or small inter-
fering RNA transfection according to the manufacturer’s
instructions (Invitrogen, Carlsbad, CA, USA). Circ-
NOLC1 was upregulated using a circ-NOLC1
overexpressing plasmid, and was knocked down using a
circ-NOLC1 shRNA expressing plasmid (the sequence is
shown in the Supplemental file). Puromycin was used to
select stable clonal cell lines. The sequence of si-ESRP1
was 5′-CUGAAGAAGUGGUGGCCUUdTdT-3′, and 3′-
AAGGCCACCACUUCUUCAGdTdT-5′.
CCK8 (Cell Counting Kit-8) assay
Cell viability was examined using the CCK8 assay. Cells
were resuspended and seeded in 96-well plates at a density
of 1500 cells per well. After the cells were plated, 10 μL of
CCK8 solution (Bintech Co., Ltd., Shanghai, China) was
added into each well at 0, 24, 48, and 72 h, and then
incubated in 5% CO2 and 37 °C for 2 h. The absorbance at
450 nm was measured using a microplate spectro-
photometer (BioTek Instruments, Winooski, VT, USA).
Wound-healing assay
Cell migration was detected using a wound-healing assay.
The cells were resuspended and seeded in six-well plates at
a density of 5 × 105 cells per well. When the cells reached
80% confluence, each well was scored vertically using a 200-
μL pipette tip. The excess suspended cells were then rinsed
off using phosphate-buffered saline (PBS) three times. Two
Fig. 5 The effect of circ-NOLC1 downregulation in vivo. Circ-NOLC1 downregulation reduced tumorigenicity in nude mice (A & B). The tumor
volumes were smaller in the sh-circ-NOLC1 group than in sh-NC group (C), Circ-NOLC1 expression (D) and ESRP1, RhoA, CDK1 protein level were all
downregulated in sh-circ-NOLC1 group than in sh-NC group (E). Comparisons between two groups were analyzed using a two-sided Student’s t test.
*p < 0.05.
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milliliters of the serum-free medium was then added to
each well and the cells were incubated at 5% CO2 and 37 °C.
The wounded cells were photographed under an optical
microscope at 0, 24, and 48 h, and the wound area was
measured using Image J software (National Institutes of
Health, Bethesda, MD, USA). The wound-healing rate was
calculated as follows: (original wound area−wound area at
each time point)/original wound area × 100%.
Cell migration assay by using cytation 5 cell imaging multi-
mode reader
Cells were plated (40,000 cells/well) in white, 96-well
clear-bottom plates (Corning) with 100 μL final volume of
complete media. When the cells were plated,
AutoScratchTM (BioTek) was used to form scratch, the
excess suspended cells were then rinsed off using PBS
three times, after which, 100 μL serum-free medium was
then added to each well and the 96-well plate was incu-
bated and imaged (every 30min) at 5% CO2 and 37 °C
using a Cytation 5 Cell Imaging Multi-Mode Reader
(BioTek Instruments, Winooski, VT, USA).
Invasion assay
The cell invasion ability was measured using a Trans-
well chamber. Matrigel matrix (BD Biosciences, San Jose,
CA, USA) was diluted 1:10 with serum-free medium. The
prepared diluted Matrigel was then uniformly added to
the upper chamber, and then the Transwell chamber was
Fig. 6 The correlation between circ-NOLC1 and ESRP1. Circ-NOLC1 overexpression or downregulation induced or inhibited ESRP1, RhoA and
CDK1 protein A or mRNA expression C–D, respectively. RIP assay confirmed the enrichment of circ-NOLC1 (B). Comparisons between two groups
were analyzed using a two-sided Student’s t test. *p < 0.05.
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Fig. 7 Silencing ESRP1 reversed circ-NOLC1’s function as an oncogene. Silencing ESRP1 inhibited cell viability A and clonal formation B, induced
apoptosis C, and reduced cell migration D and invasion E in circ-NOLC1-overexpressing CAOV3 cells, and inhibited RhoA and CDK1 protein
expression (F). Results are representative of three separate experiments; data are expressed as the mean ± SD. Comparisons between two groups
were analyzed using a two-sided Student’s t test. *p < 0.05.
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placed in an incubator for 3–4 h for coagulation. Then,
200 μL of serum-free medium containing 50,000 resus-
pended cells was added to the upper chamber, 600 μL of
complete cell culture medium was added as a chemoat-
tractant to the lower chamber, and after incubation for
48 h, the chambers were washed with PBS three times,
fixed with 5% paraformaldehyde for 15min, and then
stained with a crystal violet solution for 15min. Finally,
the cells were counted under a microscope (Olympus,
Tokyo, Japan) to evaluate cell invasion.
Plate clone formation assay
Cells (200 cells per well) were seeded into a six-well
plate, and then incubated in 5% CO2 and 37 °C for
2 weeks (complete medium) until macroscopic cell clones
appeared. The cells were carefully washed using PBS,
fixed using 4% paraformaldehyde for 15 min, stained with
Giemsa solution for 15 min, washed with tap water, and
air-dried. The colony formation rate was calculated using
the following formula: (number of clones/number of cells
inoculated) × 100%.
Apoptosis assays
Cells were collected and resuspended with 100 μL 1×
buffer containing phycoerythrin-labeled annexin V and 7-
aminoactinomycin D (5 μL each, BD) in the dark for
15min. Then, 400 μL of buffer was added and the rate of
cell apoptosis was determined using flow cytometry
within one hour.
QRT-PCR
Total RNA of tissue and cell samples was extracted
using the TRIzol reagent (Takara, Shiga, Japan). Chloro-
form (200 μL) was added into 1 mL of TRIzol, and after
Fig. 8 Silencing CDK1 or RhoA could also reverse circ-NOLC1’s function as an oncogene. Silencing CDK1 or RhoA in circ-NOLC1-overexpressing
CAOV3 cells significantly reduced cell viability A, cell migration B, and invasion C ability. CDK1 or RhoA knockdown reduced CDK1 or RhoA protein
expression, but not ESRP1 protein expression (D). Results are representative of three separate experiments; data are expressed as the mean ± SD.
Comparisons between two groups were analyzed using a two-sided Student’s t test. *p < 0.05.
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centrifugation, the upper aqueous phase was aspirated
into a new tube and an equal volume of isopropanol was
added to precipitate the RNA. After centrifugation, the
supernatant was discarded and 75% ethanol was used to
wash the RNA pellet. The precipitate was dried and dis-
solved in diethylpyrocarbonate water. The OD value at
260 nm was measured using an ultraviolet spectro-
photometer (Unico, Shanghai, China) to calculate the
concentration of RNA. Then, RNA was reverse-
transcribed to cDNA according to the manufacturer’s
instructions (Takara). Next, real-time quantitative PCR
amplification of cDNA was carried out using a SYBR
PrimeX EX-TAQ Patent II Kit (Takara, Shiga, Japan).
Finally, the cycle threshold (Ct) of the target gene and 18 S
rRNA (18 s) were compared using the 2-ΔΔCt method
(GenePharma) to determine relative expression levels of
the target gene.
Western blotting
Cells were lysed with radioimmunoprecipitation assay
buffer containing protease inhibitors. After quantification,
40 μg of denatured protein was separated using 10%
sodium dodecyl sulfate-polyacrylamide gel electrophor-
esis, followed by electro-transfer onto a polyvinylidene
difluoride membrane that had already been pre-activated
in methanol. The membrane was then washed with tris-
buffered saline and Tween 20 (TBST) for 1–2min,
blocked with 3% bovine serum albumin at room tem-
perature for 1–2 h. Thereafter, the membranes were
incubated with primary antibodies against ESRP1 (Cat
No.: 21045-1-AP), ras homolog family member A (RhoA,
Cat No.: 10749-1-AP), CDK1 (Cat No.: 19532-1-AP)
(1:1000, Proteintech Group, Chicago, IL, USA) and
β-actin (1:3000, Cat No.: 20536-1-AP, Proteintech Group)
overnight at 4 °C. On the 2nd day, the membrane was
washed with TBST three times, and then incubated with
anti-rabbit secondary antibodies at room temperature for
2 h. After washing with TBST again three times, the
immunoreactive proteins were visualized using the ECL
system (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
RNA-binding protein immunoprecipitation (RIP) assay
Bioinformatic prediction (catRAPID, http://s.
tartaglialab.com/page/catrapid_group) revealed that
ESRP1 protein could bind with circ-NOLC1. The Magna
RIP RNA-Binding Protein Immunoprecipitation Kit
(Millipore, Bedford, MA, USA) was used for the RIP assay.
In brief, A2780 cells were lysed in RIP lysis buffer and the
cell extract was incubated with RIP buffer containing
magnetic beads conjugated to human anti-ESRP1 anti-
bodies or normal rabbit IgG as a negative control.
Thereafter, to digest the proteins, the samples were
incubated with proteinase K. The immunoprecipitated
RNA was isolated and determined using qRT-PCR
analysis. Control amplification was carried out on input
RNA before immunoprecipitation, which was set as the
positive control.
Subcutaneous tumor dissemination assay
BALB/c nude mice (Vital River Laboratories, Beijing,
China) were raised in a specific pathogen-free envir-
onment. In brief, after serpentine grouping by weight,
1 × 107 circ-NOLC1-downregulated A2780 cells or
control A2780 cells in 150 µL FBS-free media were
injected into 5-week-old female mice subcutaneously
to establish the subcutaneous dissemination model. At
appropriate times after injection (Tumor size <2 cm),
the mice were euthanized and the tumor nodes were
resected and measured. All animal experiments were
approved by China Medical University Animal Care
and Use Committee and were carried out following the
Guide for the Care and Use of Laboratory Animals
(published by the National Institute of Health). No
blinding was done.
Dual-luciferase reporter assay
The wild-type or mutated PSI-check2 Dual-luciferase
vectors containing miR-326-5p, miR-330, miR-370, and
miR-9-5p binding sites on circ-NOLC1 (Hanbio Bio-
technology, Shanghai, China) were co-transfected with
miR-326-5p, miR-330, miR-370, and miR-9-5p mimics or
scrambled controls into the HEK-293T cells. Cell extracts
were prepared to measure the luciferase activity using the
Dual-Luciferase Reporter Assay System (Promega, Madi-
son, WI, USA). The relative luciferase signal was deter-
mined by the normalization of firefly luciferase activity to
that of Renilla luciferase.
Statistical analysis
Statistical analyses were performed using SPSS
20.0 software (IBM Corp., Armonk, NY, USA). Experi-
ments were repeated three times, and the mean ± SD was
used in each group of data to reflect the overall para-
meters. Comparisons between two groups were analyzed
using a two-sided Student’s t test. Correlation between
circ-NOLC1 expression and clinicopathological char-
acteristics of the patients with ovarian cancer were
examined using the χ2 test. P < 0.05 was considered sta-
tistically significant.
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